Pharmacokinetics and Pharmacodynamics of Biotech Drugs

Principles and Case Studies in Drug Development

Research output: Book/ReportBook

26 Citations (Scopus)

Abstract

This first ever coverage of the pharmacokinetic and pharmacodynamic characteristics of biopharmaceuticals meets the need for a comprehensive book in this field. It spans all topics from lead identification right up to final-stage clinical trials. Following an introduction to the role of PK and PD in the development of biotech drugs, the book goes on to cover the basics, including the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides, as well as viral and non-viral gene delivery vectors. The second section discusses such challenges and opportunities as pulmonary delivery of proteins and peptides, and the delivery of oligonucleotides. The final section considers the integration of PK and PD concepts into the biotech drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples of cetuximab and pegfilgrastim. The result is vital reading for all pharmaceutical researchers.

Original languageEnglish (US)
PublisherWiley-VCH
Number of pages403
ISBN (Print)3527314083, 9783527314089
DOIs
StatePublished - Nov 8 2006

Fingerprint

Pharmacodynamics
Pharmacokinetics
Pharmaceutical Preparations
Peptides
Antisense Oligonucleotides
Oligonucleotides
Reading
Genes
Monoclonal Antibodies
Research Personnel
Clinical Trials
Lung
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@book{5c60073fe7d445a7890f4b86a6207d44,
title = "Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development",
abstract = "This first ever coverage of the pharmacokinetic and pharmacodynamic characteristics of biopharmaceuticals meets the need for a comprehensive book in this field. It spans all topics from lead identification right up to final-stage clinical trials. Following an introduction to the role of PK and PD in the development of biotech drugs, the book goes on to cover the basics, including the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides, as well as viral and non-viral gene delivery vectors. The second section discusses such challenges and opportunities as pulmonary delivery of proteins and peptides, and the delivery of oligonucleotides. The final section considers the integration of PK and PD concepts into the biotech drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples of cetuximab and pegfilgrastim. The result is vital reading for all pharmaceutical researchers.",
author = "Bernd Meibohm",
year = "2006",
month = "11",
day = "8",
doi = "10.1002/9783527609628",
language = "English (US)",
isbn = "3527314083",
publisher = "Wiley-VCH",

}

TY - BOOK

T1 - Pharmacokinetics and Pharmacodynamics of Biotech Drugs

T2 - Principles and Case Studies in Drug Development

AU - Meibohm, Bernd

PY - 2006/11/8

Y1 - 2006/11/8

N2 - This first ever coverage of the pharmacokinetic and pharmacodynamic characteristics of biopharmaceuticals meets the need for a comprehensive book in this field. It spans all topics from lead identification right up to final-stage clinical trials. Following an introduction to the role of PK and PD in the development of biotech drugs, the book goes on to cover the basics, including the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides, as well as viral and non-viral gene delivery vectors. The second section discusses such challenges and opportunities as pulmonary delivery of proteins and peptides, and the delivery of oligonucleotides. The final section considers the integration of PK and PD concepts into the biotech drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples of cetuximab and pegfilgrastim. The result is vital reading for all pharmaceutical researchers.

AB - This first ever coverage of the pharmacokinetic and pharmacodynamic characteristics of biopharmaceuticals meets the need for a comprehensive book in this field. It spans all topics from lead identification right up to final-stage clinical trials. Following an introduction to the role of PK and PD in the development of biotech drugs, the book goes on to cover the basics, including the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides, as well as viral and non-viral gene delivery vectors. The second section discusses such challenges and opportunities as pulmonary delivery of proteins and peptides, and the delivery of oligonucleotides. The final section considers the integration of PK and PD concepts into the biotech drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples of cetuximab and pegfilgrastim. The result is vital reading for all pharmaceutical researchers.

UR - http://www.scopus.com/inward/record.url?scp=84889861270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889861270&partnerID=8YFLogxK

U2 - 10.1002/9783527609628

DO - 10.1002/9783527609628

M3 - Book

SN - 3527314083

SN - 9783527314089

BT - Pharmacokinetics and Pharmacodynamics of Biotech Drugs

PB - Wiley-VCH

ER -